Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation by Tezval, Hossein et al.
World J Urol (2009) 27:825–830
DOI 10.1007/s00345-009-0417-x
123
ORIGINAL ARTICLE 
Urocortin and corticotropin-releasing factor receptor 2 in human 
renal cell carcinoma: disruption of an endogenous inhibitor 
of angiogenesis and proliferation
Hossein Tezval · Stefanie Jurk · Farahnaz Atschekzei · 
Jan U. Becker · Olaf Jahn · Jürgen Serth · 
Markus A. Kuczyk 
Received: 26 February 2009 / Accepted: 24 April 2009 / Published online: 13 May 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Purpose Urocortin (Ucn) exerts its actions through acti-
vation of two corticotropin-releasing factor receptors
(CRFRs), CRFR1 and CRFR2. Involvement of Ucn/
CRFR2 system in pathophysiological conditions such as
the regulation of angiogenesis and inhibition of prolifera-
tion has been already reported. Suppression of neovascular-
ization through reduction of vascular endothelial growth
factor and inhibition of tumor cell cycling is modulated
mainly through activation of CRFR2. To Wnd out a possible
involvement of Ucn/CRFR2 in kidney tumor, we examined
the expression of Ucn and CRFR2 in normal and tumoral
kidney specimens.
Methods We applied reverse transcriptase PCR (n = 14),
immunoXuorescence (IF) on tissue microarrays (n = 25)
and confocal microscopy to examine the mRNA expression
and peptide/protein localization of Ucn and CRFR2 in nor-
mal kidney versus clear cell renal cell carcinoma, respec-
tively.
Results Ucn and CRFR2 mRNAs are expressed in normal
and tumor specimens. In normal tissue, IF showed a cyto-
plasmic staining of Ucn mainly in proximal tubules,
whereas a diVuse nuclear staining with diverse intensity
was observed in tumoral tissues. CRFR2 was detected in
proximal tubules and vasculature of normal specimens.
Intriguingly, an almost complete loss of CRFR2 was
observed in epithelial cells and microvessels within tumor
tissues.
Conclusions Here, and for the Wrst time, we show the
expression of Ucn and CRFR2 in human kidney and renal
cell carcinoma. We propose that the nuclear translocation
of Ucn along with the loss of CRFR2 in epithelial cells and
microvasculature of tumoral specimens may be involved in
the pathobiology of renal cell carcinoma.
Keywords Urocortin · CRFR2 · Kidney tumor · 
Angiogenesis · Proliferation
Introduction
The 40-amino acid neuropeptide urocortin (Ucn) belongs to
the corticotropin-releasing factor (CRF) peptide family.
Ucn was Wrst characterized in the rat hypothalamus and
thereafter in several central and peripheral organs of
rodents and mammals. It binds with high aYnity to both
CRF receptor 1 (CRFR1) and 2 (CRFR2). CRF receptors
(CRFRs) are G-protein coupled receptors and binding of
Ucn stimulates cAMP production subsequently activating
the protein kinase A (PKA) pathway [4, 19]. As does CRF,
also Ucn binds with high aYnity to a soluble CRF binding
protein (CRFBP). CRFBP is the only known example for a
neuropeptide binding protein and although its exact physio-
logical role still remains elusive, it is believed that CRFBP
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serves as a ligand reservoir to limit local actions of CRF-
related peptides [9]. While growth factors stimulating angi-
ogenesis have been investigated in detail, endogenous
inhibitors of angiogenesis are poorly understood. Activa-
tion of vascular CRFR2 by Ucn can eVectively suppress the
vascularization through reduction of vascular endothelial
growth factor (VEGF) [2]. As pathologic cell proliferation
and neoangiogenesis are a pre-requisite for tumorigenesis
and tumor progression, a link between the Ucn/CRFR sys-
tem and human malignancies has been demonstrated [1, 5,
20]. In particular, it is believed that the inhibition of prolif-
eration and the control of angiogenesis are mainly modu-
lated through CRFR2 [7,  21]. Clear cell renal cell
carcinoma (CC-RCC), an extremely angiogenic tumor
accounting for about 3% of all adult neoplasms, is the most
common malignancy and pathological subtype of the kid-
ney and the urological cancer with the highest lethality
[10, 16].
To gain insight into the mechanisms underlying tumori-
genesis of kidney tumor, we examined primarily the
expression of Ucn and CRFR2, as responsible factors
involved in cell proliferation and angiogenesis, in normal
and corresponding tumoral specimens derived from CC-
RCC.
Materials and methods
Tissue specimens and tissue microarray
Adult human kidney specimens (n = 25) were obtained pri-
marily from peritumoral and tumoral tissues of adult
patients undergoing nephrectomy with kidney tumors and
arranged on tissue microarray (TMA) for IF or frozen
immediately after excision for RNA isolation as described
before [18]. Intact histomorphology as examined by pathol-
ogists was used to classify the specimens as normal. Histol-
ogy of CC-RCC was approved by two pathologists. All
specimens were obtained upon approval of the local ethical
committee.
RNA isolation and reverse transcription PCR
Total RNA was extracted from frozen tissue samples
(n = 14) and the quality of total RNA was controlled as
described before [17]. Reverse transcriptase PCR was carried
out using primers speciWc for Ucn, CRFR2, and beta-tubulin
(TubA1b). Primer sequences are speciWed as following: Ucn
with access no. of AF038633, sense: 5-ACCGAGTCGAA
TATGATGC-3, antisense: 5-CCTTCTCTGTCCATTGA
CC-3 and predicted size of 113 bp, CRFR2 with access no.
of Q13324, sense: 5-GTACAGGAAGGCAGTGAAG-3,
antisense: 5-AAGACAGACACGAAGAAACC-3 and
predicted size of 163 bp. Tubulin A1b with access no. of
AF081484, sense: 5-CTC GGGCATAGTTATTGGC-3,
antisense: 5-CCGGGC TGTGTTTGTAGAC-3 and pre-
dicted size of 128 bp. RT-PCR was carried out in duplicate
after Superscript II RT and random hexamers (Invitrogen,
Carlsbad, USA) and using 2 l of RT reaction product,
0.4 M of each primer, 1 unit Taq polymerase (Quiagen,
Hilden, Germany), 0.2 mM dNTPs and 5.5 l of reaction
buVer in a total volume of 25 l as described before [17].
Total RNA from human normal prostate (R1234201-P-BC)
were obtained from Biochain Institute (Hayward, USA) as
a positive control for Ucn [1] and CRFR2 [17].
ImmunoXuorescence analysis and confocal microscopy
The paraYn-embedded tissue samples on TMA were
stained for Ucn and CRFR2 protein expression using pre-
diluted rabbit anti-human Ucn (ab27438, abcam, UK), and
goat anti-human CRFR2 (sc-20550, Santa Cruz, CA, USA)
and the standard avidin–biotin system according to the
manufacturer’s protocols (Vector Laboratories, Burlin-
game, CA, USA) with the exception that the peroxidase
substrate diaminobenzidine was replaced by Atto 488 and
Atto 655-labelled tyramides. Fluorochrome-labelled tyra-
mides were produced by coupling of N-hydroxy-
succinimide esters of Atto 488 and Atto 655 Xuorescence
dyes (Atto-Tec, Siegen, Germany) with tyramine-hydro-
chloride (T2879, Sigma-Aldrich, Germany). ModiWcations
of the protocols provided by the manufacturer and reported
by Raap et al. [15] included that 30 l of a 40 mM dye solu-
tion in DMSO and 70 l of 15 mM tyramine-hydrochloride
in 0.1 M borate buVer (pH 8.5) were incubated for 5 h at
room temperature, as described before [17]. Atto 488 and
Atto 655-labelled tyramides were applied for immunoXuo-
rescence analysis without further puriWcation at a Wnal dilu-
tion of 1:200. Confocal laser scanning microscopy was
carried out using a Leica DM IRE2 microscope. Triple Xuo-
rescence was sequentially scanned after excitation at
405 nm (DAPI), 488 nm (Atto 488) and 633 nm (Atto 655).
The imaris software was used to generate 3-dimensional
images from the image stacks obtained by confocal laser
microscopy.
Results
mRNA expression of Ucn and CRFR2 in normal kidney 
versus CC-RCC
Using reverse transcriptase PCR, speciWc signals for Ucn,
and CRFR2 mRNAs were detected in both normal and
tumoral samples (Fig. 1). As an internal control, strong
signal for TubA1b exhibited in all samples tested (Fig. 1).World J Urol (2009) 27:825–830 827
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Moreover, negative controls did not produce any signals,
whereas mRNA of Ucn and CRFR2 were readily detected
in human prostate samples as positive control (Fig. 1). Neg-
ative controls contained all reagents, except that 2-l H2O
was substituted for reverse transcriptase in the RT reaction
product (data not shown).
Peptide localization of Ucn in normal kidney 
and CC-RCC
We next examined the tissue distribution of Ucn in samples
of normal and the tumoral counterpart on TMA slides using
IF. In normal specimens, Ucn showed a cytoplasmic stain-
ing mainly in proximal tubules (Fig. 2a). Interestingly, Ucn
showed an inhomogeneous nuclear staining with diVering
intensities in tumoral tissues (Fig. 3a–d). To prove the
speciWcity of this unexpected Wnding, the anti-Ucn antibod-
ies were incubated overnight with synthetic human Ucn
prior to application in IF. This pre-treatment completely
eliminated the Ucn signal, conWrming the speciWcity of our
Ucn detection method (Figs. 2b, 5b). Moreover, epithelial
cells of prostate exhibited an intense apical immunostaining
for Ucn, further supporting that the signals for Ucn
observed in kidney specimens are indeed speciWc (data not
shown). Figure 3d shows a 3-D presentation of the nuclear
occurrence of Ucn in tumoral specimens using stacks
producing by confocal microscopy and imaris software to
generate 3-D images.
Protein localization of CRFR2 in normal kidney 
and CC-RCC
To characterize the expression pattern of CRFR2 in the
vasculature of normal and tumoral specimens in more
detail, we performed IF double staining for CRFR2 and
CD31 (Figs. 2c–d, 4a–d). CD31 was used as an endothe-
lial cell marker to facilitate identiWcation of CRFR2 in
microvessels. A cytoplasmic staining of CRFR2 could be
observed in the epithelium of proximal tubules and in the
vasculature of normal kidney (Fig. 2d). In contrast, nei-
ther epithelial cells nor vasculature of tumor tissue were
found to be positive for CRFR2 in nearly all probes exam-
ined (Fig. 4b, c). The documented signals for CRFR2
Fig. 1 Ucn and CRFR2 mRNA are expressed in human normal kid-
ney and CC-RCC. Human prostate has been used as a positive control
for Ucn and CRFR2. TubA1b expression has been shown as an inter-
nal control in all tested specimens
Fig. 2 Expression of Ucn and 
CRFR2 in normal kidney speci-
mens. Proximal tubules of kid-
ney express Ucn (a). Blocking 
experiment omitted the observed 
signal for Ucn in normal kidney 
specimens (b). c, d exhibit the 
speciWc signals by double 
immunostaining for CD31 and 
CRFR2, respectively, in 
vasculature of normal kidney828 World J Urol (2009) 27:825–830
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could be omitted using a speciWc blocking experiment by
blocking peptide of CRFR2 (sc-20550-P, Santa Cruz, CA,
USA) (Fig. 5a). This blocking experiment beside positive
controls in heart and prostate specimens underlined the
speciWcity of the CRFR2 immunoreactivity signals (data
not shown).
Fig. 3 Nuclear expression 
of Ucn in CC-RCC has been 
demonstrated in a. DAPI and 
magniWed image of a are shown 
in b and c, respectively. 
d Demonstrates a 3-D 
presentation and speciWes the 
nuclear occurrence of Ucn in 
yellow color in the nucleus of a 
CC-RCC in blue
Fig. 4 Double staining and 
merged presentation of CD31 
and CRFR2 in CC-RCC has 
been shown in a–c. CD31 spe-
ciWc signals in microvessels of 
CC-RCC (a). No positivity for 
CRFR2 could be observed in 
the vasculature of CC-RCC 
(b). c shows the merged image 
of a and b and DAPI. Merged 
image of c and d, and DAPI with 
expression of CRFR2 in the vas-
culature of normal kidney (d)World J Urol (2009) 27:825–830 829
123
Discussion
There are very limited data on the expression of Ucn in
human malignancies. Ucn expression is down-regulated in
human endometrial carcinoma, whereas it was found to be
unaltered in prostate adenocarcinoma in comparison to
benign prostatic hyperplasia [1,  5]. Furthermore, both
reports indicated a cytoplasmic staining of Ucn in tumor
cells. In this study, we observed for the Wrst time that Ucn
is present in diVerent subcellular compartments depending
on whether the specimens are derived from normal or
tumoral tissues. In normal specimens, cytoplasmic expres-
sion of Ucn was mainly observed in proximal tubules,
whereas a diVuse nuclear immunostaining was detected in
CC-RCC specimens. Transport across the nuclear enve-
lope occurs through the nuclear pore complex (NPC).
Small proteins are believed to cross the meshwork formed
by nucleoporins by diVusion [6]. This may require the
presence of nuclear localization signals (NLS). Thus,
production of certain cofactors by diVerent cell types
in diVerent stages of development or under special
(patho)physiologic conditions can regulate which cargo is
imported into the nucleus [14]. As a 40-amino acid pep-
tide, it is likely that Ucn can passively pass the nuclear
envelope and pores, and this may even apply to the Ucn
precursor (26 kD). Open questions include whether there is
an yet unidentiWed carrier protein involved in an active
transport of Ucn into the nucleus. Although rather believed
to be a secreted protein, even a potential involvement of
CRFBP should not be excluded prematurely. There are
several lines of evidence underscoring the importance of
protein localization in cancer biology and target therapy
[22]. Recently, Wang et al. demonstrated that the ErbB
family proteins migrate into the nucleus of cancer cells
where they can act as transcriptional factors and are
closely related to cancer cell proliferation and metastasis
[8]. Considering the inhomogeneous nuclear positivity of
Ucn in tumoral tissues, a correlation study of Ucn nuclear
positivity with clinicopathological parameters of CC-RCC
specimens in a large number of patients collectively is of
great interest. How the protein functions are regulated in
diVerent cellular locations is not known. An intrinsic
autonomous property of the protein along with diVerent
binding factors in diVerent locations might be involved in
this form of molecular traYcking.
Activation of vascular CRFR2 inhibits neovasculariza-
tion in vivo and in vitro by reduction of VEGF [2,  7].
Tumor cells and vessels of CC-RCC demonstrated no sig-
nal for CRFR2 antibody (Fig. 4b, c). Recently, we reported
the same phenomenon in the vasculature of prostate carci-
noma [17]. In contrast to CC-RCC, prostate cancer exhib-
ited no signal for CRFR2 mRNA in PCR analysis.
However, CC-RCC did not translate CRFR2 gene either.
Thus, the CRFR2 mRNA and gene translation seem to be
diVerentially regulated in diVerent cancer entities but in
deed the CRFR2 is silenced at least in both CC-RCC and
prostate cancer. Loss of CRFR2 expression in microvessels
of CC-RCC, a known hypervascularized tumor, is in agree-
ment with the Wnding that CRFR2-deWcient mice showed
an extensive vascularization and increase in VEGF level in
comparison to wild-type animals [2]. Moreover, treatment
of CRFR2 wild-type animals with Ucn signiWcantly
decreased the expression of VEGF [2]. Upregulation of
VEGF and VEGF receptors in CC-RCC has been reported
frequently. Inverse expression of CRFR2 and VEGF in
renal cancer Wts to the mentioned CRFR2 knock out results
and our present Wndings. It is therefore attractive to hypoth-
esize that the systemic pharmacologic activation of CRFR2
represents a novel strategy for an anti-angiogenesis treat-
ment of kidney tumors through inhibition of the vasculari-
zation of peritumoral tissues. This anti-progressive eVect
may be further enhanced by an agonist-driven induction of
CRFR2 expression within the microvasculature of kidney
tumors. In support of this hypothesis, exposure of Lewis
lung carcinoma cells to CRFR2-speciWc agonists in cell
culture revealed an inducible expression of CRFR2 [7].
Under normal conditions in the kidney, cell turnover
is signiWcantly higher in distal tubules than in proximal
tubules [11, 13]. Thus, co-localization of Ucn and CRFR2
in normal proximal tubules may reXect the antiproliferative
action of the Ucn/CRFR2 system [3, 7] which seems to be
disturbed in tumoral cells. Our Wndings further support the
notion that the cell cycle regulatory function of a speciWc
system strongly depends on the cell types involved and/or
the subcellular localization. In particular, nuclear transloca-
tion can be cell cycle-dependent as shown for many
Fig. 5 a, b show the blocking 
experiment and complete block-
ade of CRFR2 and Ucn signals 
in normal kidney and CC-RCC, 
respectively830 World J Urol (2009) 27:825–830
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proteins regulating cell proliferation [12,  23, 24]. There-
fore, it can be assumed that Ucn translocates into the
nucleus to regulate the cell proliferation (independent of
CRFR2) which it ultimately fails in cancer cells for yet
unknown reasons.
Conclusions
In summary here, and for the Wrst time, we present the
altered expression of Ucn/CRFR2 as an endogenous inhibi-
tor of angiogenesis and proliferation, in human kidney can-
cer and this may improve the fundamental understanding of
cancer target therapy and cancer biology.
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